ADP-ribosylation factor like GTPase 6 interacting protein 5
RGD ID:
708572
Description:
Enables transmembrane transporter binding activity. Involved in negative regulation of transport and regulation of neurotransmitter uptake. Predicted to be located in cytoskeleton and endoplasmic reticulum membrane. Predicted to be active in plasma membrane and presynaptic cytosol. Orthologous to human ARL6IP5 (ADP ribosylation factor like GTPase 6 interacting protein 5); INTERACTS WITH 2,3,7,8-tetrachlorodibenzodioxine; 6-propyl-2-thiouracil; ammonium chloride.
ADP-ribosylation factor-like 6 interacting protein 5; ADP-ribosylation factor-like protein 6-interacting protein 5; ADP-ribosylation-like factor 6 interacting protein 5; aip-5; ARL-6-interacting protein 5; glutamate transporter EAAC1 interacting protein; glutamate transporter EAAC1-interacting protein; Gtrap3-18; PRA1 family protein 3; prenylated Rab acceptor protein 2; protein JWa
ARL6IP5 protein affects the susceptibility to [Fluorouracil co-treated with Leucovorin co-treated with Cisplatin] and ARL6IP5 protein affects the susceptibility to [Fluorouracil co-treated with Leucovorin co-treated with oxaliplatin]
ARL6IP5 protein affects the susceptibility to [Fluorouracil co-treated with Leucovorin co-treated with Cisplatin] and ARL6IP5 protein affects the susceptibility to [Fluorouracil co-treated with Leucovorin co-treated with oxaliplatin]
[arsenite co-treated with Benzo(a)pyrene] results in increased expression of ARL6IP5 mRNA and [Benzo(a)pyrene results in increased activity of AHR protein] which results in increased expression of ARL6IP5 mRNA
[arsenic trioxide results in increased abundance of Hydrogen Peroxide] which results in increased expression of ARL6IP5 protein and CAT protein inhibits the reaction [[arsenic trioxide results in increased abundance of Hydrogen Peroxide] which results in increased expression of ARL6IP5 protein]
benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [ARL6IP5 mutant form inhibits the reaction [Morphine results in increased expression of OPRD1 protein]]
[LDN 193189 co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with FGF2 protein] results in increased expression of ARL6IP5 protein